Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Grassley Places Hold On Von Eschenbach

This article was originally published in The Pink Sheet Daily

Executive Summary

The FDA commissioner nominee may have to wait as the senator complains about ignored subpoenas and delayed responses by the agency to committee requests.

You may also be interested in...



Ketek Medication Guide Suggested By FDA Staff

Two-day, two-panel advisory committee meeting will consider the risks and benefits of the antibiotic, which Sanofi-Aventis says addresses an unmet medical need.

Ketek Medication Guide Suggested By FDA Staff

Two-day, two-panel advisory committee meeting will consider the risks and benefits of the antibiotic, which Sanofi-Aventis says addresses an unmet medical need.

Senate May Take Up Von Eschenbach Nomination For Vote Thursday

Majority Leader Frist and 16 GOP senators file motion that could override holds.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS063392

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel